Study of the Reversibility of Glucose Intolerance Caused by Chronic Aspartame Consumption
NCT ID: NCT02520258
Last Updated: 2020-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
75 participants
INTERVENTIONAL
2015-08-31
2019-06-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Aspartame on Appetite, Body Composition and Oral Glucose Tolerance
NCT02999321
Enteroendocrine Hormonal Response After the Ingestion of Cola Beverages With Sucrose and Non-nutritive Sweeteners
NCT05654285
Sugar-replacement Sweeteners, and Blood Sugar Control
NCT01128829
Effect of Artificial Sweetener (AFS) on Glucose Metabolism in Patients with Type 1 Diabetes (T1D)
NCT06315725
Effects of Artificial Sweeteners on Gut Microbiota and Glucose Metabolism
NCT02569762
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators plan to study two (2) cohorts of healthy volunteers: 1) Those who regularly drink at least three cans per day of diet soda that contains aspartame (Cohort 1, Aspartame Consumers) and 2) participants who consume less than or equal to two (2) cans of diet soda per week (Cohort 2, Aspartame Naïve Participants).
Phase I of the study, the investigators will ask participants questions about their usual diet, including how much diet soda they usually drink. Participants will be screened by a test called the oral glucose tolerance test, or OGTT. This test involves coming to the hospital to drink sugary syrup, then have blood sugar checked every thirty (30) minutes for five (5) hours. Before the test, participants must refrain from eating or drinking anything for ten (10) hours. If the OGTT shows a high value, then the participant in cohort 1 (Aspartame Consumers) who regularly drink 3 or more cans per day of diet soda will be approached about continuing into the second phase of the study. For the participants in cohort 2 (consume less than or equal to two (2) cans of diet soda per week; Aspartame Naïve Participants), this will be the end of their participation in the study.
Phase II of the study, blood tests, OGTT, stool samples, and weight and body fat measurements a few times a week will track any changes in the participants during the study. During the phase II five (5) week study, participants will receive all of their meals from the Rockefeller University Hospital and should not have any outside food or drinks. The diet used throughout this study phase (II) is the Prudent Metabolic Diet. Participants can leave the hospital and continue to work, but must come for all tests and to receive meals. During Week One, participants will eat only food provided by the hospital but will continue to drink three (3) cans of diet soda per day. In Weeks Two through Four, participants will continue to eat food given to them by the hospital and will not be allowed to consume any foods or drinks that contain aspartame. In Week Five, participants will continue on the hospital diet, but will again start drinking three (3) cans of diet soda per day.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aspartame Consumers - Cohort 1
Experimental Group/Arm
Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).
Phase II - (If OGTT results are abnormal, participants will be invited to participate in Phase II) Five (5) week study phase with Prudent Metabolic Diet and Intervention of diet soda containing aspartame only; Week 1: Prudent Metabolic Diet and 36oz diet soda po daily, Week 2-4: Prudent Metabolic Diet and no diet soda, Week 5: Prudent Metabolic Diet and 36 oz diet soda po daily.
Oral glucose tolerance test (OGTT)
OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).
Diet soda containing aspartame only
7 days of 36 oz diet soda po daily (Week 1), followed by 21 days washout (Weeks 2-4), and 7 days rechallenge (Week 5); Prudent metabolic diet; Oral glucose tolerance test (OGTT) on days (+/-2) 3, 7, 10, 14, 21, 28, 31, 35
Aspartame Naive Participants - Cohort 2
Control Group/Arm
Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).
Phase II - Not applicable for this cohort.
Oral glucose tolerance test (OGTT)
OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral glucose tolerance test (OGTT)
OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).
Diet soda containing aspartame only
7 days of 36 oz diet soda po daily (Week 1), followed by 21 days washout (Weeks 2-4), and 7 days rechallenge (Week 5); Prudent metabolic diet; Oral glucose tolerance test (OGTT) on days (+/-2) 3, 7, 10, 14, 21, 28, 31, 35
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Weight stable for at least 3 months prior to screening (\< 5% weight change)
3. BMI of 21 - 29
4. Cohort 1 - Aspartame Consumers: Primary dietary sweetener is aspartame; consumes at least 36 ounces of diet soda in which aspartame is a primary ingredient (Diet Coke or Diet Dr Pepper) a day for at least 6 months duration prior to study enrollment (Primary dietary sweetener is aspartame" should be defined as: "840g per week sucrose equivalent from aspartame and less than 280 grams per week sucrose equivalent from all other sweeteners (non-caloric and caloric sweeteners). For reference, one 12oz soda is 40g sucrose equivalent, and one teaspoon (one packet) of artificial sweetener is 4g sucrose equivalent.)"
Cohort 2 - Aspartame Naïve Participants: Consumes less than or equal to 2 cans of diet soda per week
5. Screening Visit #2 OGTT Outcome:
* 0-h plasma glucose \< 110 mg/dl AND
* 2-h plasma glucose \< 140 mg/dl
6. Abnormal OGTT during the screening phase of the study (area under curve on the high end of distribution)
7. Must be able to comply with a metabolic Prudent diet
8. Willing to fast 10 hours before each OGTT and BodPod
9. Current level of exercise (aerobic and/or resistance training) must be able to be sustained while an in-patient
Exclusion Criteria
Clinical Identification of the Metabolic Syndrome (must have 3 or more of the following risk factors):
Abdominal Obesity, given as a waist circumference:
* Men \>102 cm (\>40 in)
* Women \> 88 cm (\>35 in)
Triglycerides \>150 mg/dl
HDL Cholesterol:
* Men \< 40 mg/dl
* Women \<50 mg/dl
Blood Pressure \>130/ \>85 mm Hg
Fasting Glucose \> 110 mg/dl
2. Average systolic blood pressure (SBP) \> 150 mmHg and / or diastolic blood pressure (DBP) \> 90 mmHG (based on 3 BPs taken at screening visit #1),
3. LDL-C \> 240mg/dl
4. Triglycerides \> 400 mg/dl
5. Evidence of a liver disorder (ALT \> three fold of the ULN)
6. Evidence of any renal disease
7. Currently on a weight-loss diet
8. Diabetes
9. Self-reported history of thyroid dysfunction
10. Sugar sweetened beverage consumption (\> 84 ounces per week)
11. Hemoglobin \<13.0 g/dl for males and 12.0 g/dl for females
12. Current, prior (within 2 months), or anticipated use of any of the following medications:
antihyperlipidemic, hyperglycemic medications, Antineoplastics, Antiretrovirals, Selective Serotonin Reuptake Inhibitors, Diuretics, Antihypertensives, Anticonvulsants, Hormone therapy, Birth control
13. Self-reported antibiotic use within the previous 3 months
14. Currently pregnant or lactating
15. History of cardiac disease
16. Active illegal drug user (self-reported)
17. History of GI surgery (gastric bypass, bariatric, Roux-en-Y, colon resection, etc.)
18. Habitual ingestion of \> 2 alcoholic beverages/day
19. Ever diagnosed with an eating disorder (self-reported)
20. Use of steroids or beta agonists (orally, intranasal or inhaled) within a week of any OGTT
21. Positive Hepatitis Serology (Hep. B surface Antibody; Hep. B surface antigen; Hep. C surface antibody)
22. HIV Positive
23. Tobacco use within the past 3 months
24. Any medical or social condition that, in the opinion of the Investigator, might pose additional risk to the participant or confound the results of the study
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rockefeller University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thomas Huber
Research Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Huber, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Rockefeller University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Rockefeller University
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
THU-0887
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.